| Identification | Back Directory | [Name]
1,3,6,8-tetraazatricyclo[6.2.1.13,6]dodecane, stereoisomer | [CAS]
18304-79-5 | [Synonyms]
SMBA2
SMBA-2
SMBA 2
Einecs 242-188-9
1,3,6,8-Tetraazatricyclo[6.2.1.13,6]dodecane
1,3,6,8-tetraazatricyclo[6.2.1.13,6]dodecane, stereoisomer | [EINECS(EC#)]
242-188-9 | [Molecular Formula]
C8H16N4 | [MDL Number]
MFCD21608406 | [MOL File]
18304-79-5.mol | [Molecular Weight]
168.24 |
| Hazard Information | Back Directory | [Uses]
Bax agonist 1 (compound SMBA2) is a Bax agonist (Ki=57.2 nM). Bax agonist 1 induces Bax conformational changes by blocking S184 phosphorylation, promoting Bax insertion into the mitochondrial membrane and forming Bax oligomers, which induce cytochrome c release and apoptosis in malignant cancer cells expressing Bax. Bax agonist 1 can be used in lung cancer research[1]. | [Definition]
ChEBI: 1,3,6,8-tetraazatricyclo[6.2.1.1(3,6)]dodecane is an azatricycloalkane that is tricyclo[6.2.1.1(3,6)]dodecane in which the four bridgehead CH groups are replaced by nitrogen atoms. It is a small-molecule BAX agonist. It has a role as an apoptosis inducer and an antineoplastic agent. It is a bridged compound, a tetramine and an azatricycloalkane. | [IC 50]
Bax: 57.2 nM (Ki) | [References]
[1] Meiguo Xin, et al. Small-molecule Bax agonists for cancer therapy. Nature communications 5.1 (2014): 4935. DOI:10.1038/ncomms5935 |
|
|